Financial Results for the Fiscal Year Ended March 31, 2019 (FY2018)

from the beginning

“Review: Ashitaka Shipping Delays”“Strengthen Global Operations”

Review: Ashitaka Shipping Delays

• Quickly Normalized, Impact Minimized

• Preventive Actions

Strengthen Global Operations

• Global Production System

• Global Production System (Cardiac & Vascular)

• Global Production System (General Hospital)

• Global Production System (Blood Management)

• Global Production System (31 factories)

• Toward Strengthening Global Operations

• (1) Global Optimization: Cardiac & Vascular TIS Case

• (2) Strengthen Organization

• (3) Collaboration Across Businesses/Companies Cases

• (4) Local Production: China Case

• Monozukuri Evolution: From Implicit to Explicit; Pass on within The Group

• Mid‐ to Long Term Vision

@

Financial Results for the Fiscal Year Ended March 31, 2019 (FY2018)

• Both Revenue and Profit in Line w/ the Revised Guidance

• FY18 Results in Comparison to the Original Guidance

• Adjusted Operating Profit: Adjustments

• Adjusted Operating Profit Variance Analysis

• Revenue by Region

• Revenue by Business Segment

• Cardiac and Vascular : Revenue Increase by Overcoming the Shipping Delays

• General Hospital: Steady in Profit of All Businesses

• Blood Management: Back to Positive Profit Growth w/ Steady Revenue

• Major Topics in FY18

• New Products Pipeline in FY18

• FY19 Guidance

• FY19 Annual Guidance: Adjusted Operating Profit

• FY19 Guidance

• New Products Pipeline in FY19

• FY18 Year‐end Dividend Proposal: 27.0 JPY

Reference(Slide only)

• FY18 Revenue and Growth by Region

• Operating Expenses

• Quarterly Results

• CAPEX and R&D Expenses

• FY18 Cash Flow

• Foreign Exchange Sensitivity

• The Status of Convertible Bonds

IR Contact